WO2025230540 - IMPROVED TREATMENT OF BREAST AND OTHER CANCERS USING ZINC CHLORIDE INSTEAD OF RADIATION
National phase entry is expected:
Publication Number
WO/2025/230540
Publication Date
06.11.2025
International Application No.
PCT/US2024/027855
International Filing Date
03.05.2024
Title **
[English]
IMPROVED TREATMENT OF BREAST AND OTHER CANCERS USING ZINC CHLORIDE INSTEAD OF RADIATION
[French]
TRAITEMENT AMÉLIORÉ DU CANCER DU SEIN ET D'AUTRES CANCERS À L'AIDE DE CHLORURE DE ZINC AU LIEU DE RAYONNEMENT
Applicants **
BROOKS, Norman, Asher
Inventors
BROOKS, Norman, Asher
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2521 | |
| EPO | Filing, Examination, Granting | 14745 | |
| Japan | Filing, Examination, Granting | 2678 | |
| South Korea | Filing, Examination, Granting | 3165 | |
| USA | Filing, Examination, Granting | 7910 |
Total:
31,019
Contact Us
Abstract[English]
An improved method for treating breast cancer using zinc chloride as an alternative to radiation is provided. Zinc chloride is a deeply penetrating topical medicine that kills cancerous tissue equivalent to radiation. Radiation is time-consuming, costly, and can cause severe radiation-related adverse events, including secondary cancers, lung, and heart damage. An analysis of 20,000 women showed that radiation was able to reduce mortality by 13.2% from breast cancer, but this improvement was offset by radiation mortality from adverse events of 21.2% [Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials, Lancet 2,000:355:May 20,2000]. This invention allows the surgeon to destroy residual malignant tissue that surrounds a breast cancer lumpectomy wound equivalent to radiotherapy without the mortality of radiation.[French]
L'invention propose une méthode améliorée de traitement du cancer du sein à l'aide de chlorure de zinc en tant qu'alternative au rayonnement. Le chlorure de zinc est un médicament topique profondément pénétrant qui tue le tissu cancéreux équivalent au rayonnement. Le rayonnement est chronophage, coûteux et peut provoquer des événements indésirables graves liés au rayonnement, y compris des cancers secondaires et des lésions du poumon et cardiaques. Une analyse de 20 000 femmes a montré que le rayonnement était en mesure de réduire la mortalité de 13,2 % du cancer du sein, mais cette amélioration a été contrebalancée par une mortalité liée au rayonnement suite à des événements indésirables de 21,2 % (Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials, Lancet 2,000:355:May 20,2000). La présente invention permet au chirurgien de détruire un tissu malin résiduel qui entoure une plaie de tumorectomie du cancer du sein équivalente à une radiothérapie sans la mortalité du rayonnement.